We all know people - don't we? Why not introduce a hiring manager to a professional and get paid? Maybe get more business on a long run. Its simple - checkout www.ntroduction.com

We may know people who are hiring - why not introduce them to a deserved candidate? You can get rewarded and maybe also get more business on a long run. Check out www.ntroduction.com

How to get introduced to hiring managers or Customer in this market?

Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Dr. Charles Dinarello, Chief Scientific Officer of OmniBio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology. The paper describes the use of Alpha 1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation. Mice survive the crisis with AAT treatment. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Who you know is more important than what you know? Get introduced to a hiring manager! Job seekers- take advantage at www.NTRODUCTION.com

With ntroduction.com you can ask for an introduction to a hiring manager! Check out ntroduction.com

OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

In this video I take a more in depth look at gaming on the Archos 70 Internet Tablet. This is then followed by a look at the supplied AppsLib app and Android Market which I installed to the device via an apk file. More Archos 70 videos on the Geekanoids Channel soon. Useful Links Manufactured by: www.archos.com Supplied by: www.amp3.co.uk Sponsor: www.mymemory.com YouTube Channel: www.youtube.com Website: www.geekanoids.co.uk Twitter: www.twitter.com

market.android.com This is an overview of the new Android Market website that allows you to install apps over the air, directly to your Android device. No data cables needed. Twitter: www.twitter.com Like Us On Facebook: on.fb.me